Using Technology to Maintain the Education of Residents During the COVID-19 Pandemic

Robert C. Chick, Guy T. Clifton, Kaitlin M. Peace, +4

Journal of surgical education

Epidemic IntelligenceGlobal Health CrisisCovid-19 PandemicDigital HealthEducation +6

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

Elizabeth A. Mittendorf, Alexandros Ardavanis, Jennifer K. Litton, +8

Oncotarget

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Elizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski, +12

Annals of Oncology

VaccinationBreast OncologyBreast Cancer PatientsMedicineImmunology +8

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Guy T. Clifton, Diane F. Hale, Timothy J. Vreeland, +10

Clinical Cancer Research

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Tommy A. Brown, Elizabeth A. Mittendorf, Diane F. Hale, +18

Breast Cancer Research and Treatment

Prone positioning improves oxygenation in adult burn patients with severe acute respiratory distress syndrome

Diane F. Hale, Jeremy W. Cannon, Andriy I. Batchinsky, +6

The Journal of Trauma: Injury, Infection, and Critical Care

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Robert C. Chick, Guy T. Clifton, Diane F. Hale, +13

Clinical Immunology

Breast OncologyMedicineImmunologyPathologyImmune Checkpoint Inhibitor +6

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, +13

Annals of Surgical Oncology

Tlpldc VaccineSurgical OncologyOncologyMelanomaImmunology +5

Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland, +14

Cancer Medicine

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Julia M. Greene, Erika J Schneble, Doreen O. Jackson, +9

Cancer Immunology Immunotherapy

Tumor ImmunologyCancer ImmunosurveillanceMelanomaImmunologyTherapeutic Vaccine +6